Adventitial Delivery of an Allogeneic Bone Marrow-Derived Adherent Stem Cell in Acute Myocardial Infarction Phase I Clinical Study

Title

Adventitial Delivery of an Allogeneic Bone Marrow-Derived Adherent Stem Cell in Acute Myocardial Infarction Phase I Clinical Study

Creator

Penn M S; Ellis S; Gandhi S; Greenbaum A; Hodes Z; Mendelsohn F O; Strasser D; Ting A E; Sherman W

Publisher

Circulation Research

Date

2012
2012-01

Description

Rationale: MultiStem is an allogeneic bone marrow-derived adherent adult stem cell product that has shown efficacy in preclinical models of acute myocardial infarction (AMI). In this phase I clinical trial in patients with first ST-elevation-myocardial infarction (STEMI), we combine first-in-man delivery of MultiStem with a first-in-coronary adventitial delivery system to determine the effects of this system on left ventricular function at 4 months after AMI. Objective: Test the effects of adventitial delivery of Multistem in the peri-infarct period in patients with first STEMI. Methods and Results: This study was a phase I, open-label, dose-escalating registry control group study. Nineteen patients received MultiStem (20 million, n=6; 50 million, n=7; or 100 million, n=6) and 6 subjects were assigned to the registry control group. Two to 5 days after AMI, we delivered MultiStem to the adventitia of the infarct-related vessel in patients with first-time STEMI. All patients underwent primary percutaneous coronary intervention with resulting Thrombolysis In Myocardial Infarction grade 3 flow and with ejection fraction (EF) <= 45% as determined by echocardiogram or left ventriculogram within 12 hours of primary percutaneous coronary intervention. The cell product (20 million, 50 million, or 100 million) was well tolerated, and no serious adverse events were deemed related to MultiStem. There was no increase in creatine kinase-MB or troponin associated with the adventitial delivery of MultiStem. In patients with EF determined to be <= 45% by a core laboratory within 24 hours before the MultiStem injection, we observed a 0.9 (n=4), 3.9 (n=4), 13.5 (n=5), and 10.9 (n=2) percent absolute increases in EF in the registry, 20 million, 50 million, and 100 million dose groups, respectively. The increases in EF in the 50 million and 100 million groups were accompanied by 25.4 and 8.4 mL increases in left ventricular stroke volume. Conclusions: In this study, the delivery of MultiStem to the myocardium in patients with recent STEMI was well tolerated and safe. In patients who exhibited significant myocardial damage, the delivery of >= 50 million MultiStem resulted in improved EF and stroke volume 4 months later. These findings support further development of MultiStem in patients with AMI and they validate the potential of a system for delivery of adult stem cells at any time after primary percutaneous coronary intervention. (Circ Res. 2012;110:304-311.)

Subject

adventitia; Cardiovascular System & Cardiology; clinical-trial; double-blind; Heart failure; Hematology; myocardial infarction; progenitor cells; regeneration; stem-cells; transplantation

Format

Journal Article

Search for Full-text

Users with a NEOMED Library login can search for full-text journal articles at the following url: https://libraryguides.neomed.edu/home

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Pages

304-+

Issue

2

Volume

110

Citation

Penn M S; Ellis S; Gandhi S; Greenbaum A; Hodes Z; Mendelsohn F O; Strasser D; Ting A E; Sherman W, “Adventitial Delivery of an Allogeneic Bone Marrow-Derived Adherent Stem Cell in Acute Myocardial Infarction Phase I Clinical Study,” NEOMED Bibliography Database, accessed May 10, 2024, https://neomed.omeka.net/items/show/6750.